Gastric cancer
Conditions
Interventions
None listed
Sponsors
Sapporo Medical University School of Medicine, Department of Medical Oncology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) had a histologically proven gastric adenocarcinoma (2) had a performance status (PS) of 0-2 on the Eastern Cooperative Oncology Group scale (3) aged 20-80 years (4) received DCS as first-line therapy for either metastatic or unresectable disease, with PM confirmed by image diagnosis such as computed tomography (CT), macroscopic evaluation or cytology (5) no prior chemotherapy other than adjuvant chemotherapy, which was required to have been completed 6 months before enrollment (6) received no other concomitant targeted therapy, such as trastuzumab (7) had documented follow-up with a physician and a radiographic tumor evaluation (8) showed adequate bone marrow, liver, and renal function (9) no other serious medical conditions (10) life expectancy 3 months (11) not pregnant or breast-feeding (12) provided written, informed consent.
Exclusion criteria
Exclusion criteria: (1)Patients with active double cancer (2) Any other patients who are regarded as unsuitable for this study by the investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Response rate Progression-free survival Adverse events Drug exposure | — |
Countries
Japan
Contacts
Public ContactHiroyuki Ohnuma
Sapporo Medical University School of Medicine Department of Medical Oncology
Outcome results
None listed